Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
.webp)
Evidence from recent clinical trials Recent clinical trials show that semaglutide is effective for weight loss in adult patients
Methods An in vitro model of PCOS was constructed by treating KGN cells with dihydrotestosterone (DHT), and PLB treatment, YTHDF1 knockdown (si-YTHDF1), and SLC7A5 overexpression (pcDNA 3.1-SLC7A5) were intervened respectively
Supplemental Figure 4A), indicating that acetyl-CoA is available in both the nucleus and cytosol in these cells
This is where the real complexity begins
